Recommendations from the AAPS LBABFG Biosimilars Action Program Committee for the Validation Of Pharmacokinetic and Immunogenicity Assays in Support of Biosimilar Drug Development
able to pick out bioanalytical differences between the Biosimilar and Innovator. Pharmacokinetic and Immunogenicity assays are the major measurement platforms for safety and efficacy data arising from non clinical

